Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elys BMG Group, Inc.ELYS · Entity 91339 | Director | February 14, 2023 | February 16, 2023 |
| Theriva Biologics, Inc.TOVX · Entity 7919 | Director · CEO and CFO | January 05, 2026 | January 06, 2026 |
| Twin Vee PowerCats, Co.VEEE · Entity 8235 | Director | July 23, 2021 | July 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elys BMG Group, Inc.
Report date February 14, 2023 · Filed February 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,717 |
Reported balance
After 2023-02-14 transaction · row 1
1 source rowRow 1 · 2023-02-14 · Grant · Acquired 22,472 · Balance 27,717 F1: These shares were issued under the Cmpany's Stock Incentive plan, as amended, in lieu of director fees that were owed to Mr. Shallcross. |
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2033-02-14 | Direct | 39,377 |
Reported balance
After 2023-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-14 · Grant · Acquired 39,377 · Balance 39,377 F2: These stock options were issued under the Company's Stock Incentive Plan, as amended, and vest immediately |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2033-02-14 | Direct | 92,254 |
Reported balance
After 2023-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-14 · Grant · Acquired 92,254 · Balance 92,254 F3: These stock options were issued under the Company's Stock Incentive plan, as amended, and vest as to 15,376 immediately and 76,878 pro-rata over ten months. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued under the Cmpany's Stock Incentive plan, as amended, in lieu of director fees that were owed to Mr. Shallcross.
F2: These stock options were issued under the Company's Stock Incentive Plan, as amended, and vest immediately
F3: These stock options were issued under the Company's Stock Incentive plan, as amended, and vest as to 15,376 immediately and 76,878 pro-rata over ten months.
Theriva Biologics, Inc.
Report date January 05, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2033-01-04 | Direct | 475,000 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 475,000 · Balance 475,000 F1: These stock options vest pro rata on a monthly basis over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest pro rata on a monthly basis over 36 months.
Twin Vee PowerCats, Co.
Report date July 23, 2021 · Filed July 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.80 · Expires 2031-06-08 | Direct | 5,500 |
Reported balance
After 2021-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-23 · Grant · Acquired 5,500 · Balance 5,500 F1: Consists of options to purchase 5,500 shares of our common stock that vest pro rata on a monthly basis over 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of options to purchase 5,500 shares of our common stock that vest pro rata on a monthly basis over 12 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 6, 2026 21:55 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 475,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001104659-26-001388 · tm262266-4_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2033-01-04 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:01 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 190,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-25-043510 · tm2513725-3_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-04-29 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 21:07 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 700,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-126396 · tm2332964-4_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2030-12-14 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 11:00 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 14,000 | $0.69 | $9,703.40 |
DisclosureSEC source: 0001104659-23-069136 · tm2318170-1_4seq1.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6699 through $0.699, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 11:00 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 26,000 | $0.63 | $16,452.80 |
DisclosureSEC source: 0001104659-23-068719 · tm2318003-1_4seq1.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6015 through $0.6659, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:39 UTC | Elys BMG Group, Inc. ELYS · Entity 91339 | GrantStock Option (right to buy) · Derivative | 92,254 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001017386-23-000063 · ownership.xml · derivative · entry 3 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,254 Underlying: Common Stock · 92,254 shares Expires 2033-02-14 F3 · derivative.exercise_date: These stock options were issued under the Company's Stock Incentive plan, as amended, and vest as to 15,376 immediately and 76,878 pro-rata over ten months. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:39 UTC | Elys BMG Group, Inc. ELYS · Entity 91339 | GrantStock Option(right to buy) · Derivative | 39,377 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001017386-23-000063 · ownership.xml · derivative · entry 2 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,377 Underlying: Common Stock · 39,377 shares Expires 2033-02-14 F2 · derivative.exercise_date: These stock options were issued under the Company's Stock Incentive Plan, as amended, and vest immediately Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:39 UTC | Elys BMG Group, Inc. ELYS · Entity 91339 | GrantCommon Stock | 22,472 | $0.89 | $20,000.08 |
DisclosureSEC source: 0001017386-23-000063 · ownership.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,717 F1 · shares: These shares were issued under the Cmpany's Stock Incentive plan, as amended, in lieu of director fees that were owed to Mr. Shallcross. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 11:06 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 25,000 | $1.04 | $26,075.00 |
DisclosureSEC source: 0001104659-23-018901 · tm236426-1_4.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.02 through $1.05, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 11:02 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 25,000 | $0.94 | $23,512.50 |
DisclosureSEC source: 0001104659-23-010108 · tm235343-1_4seq1.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 11:03 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 25,000 | $0.87 | $21,825.00 |
DisclosureSEC source: 0001104659-23-006677 · tm234482-1_4seq1.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.860 through $0.875, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 11:08 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 25,000 | $0.75 | $18,705.00 |
DisclosureSEC source: 0001104659-23-005546 · tm234103-1_4.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 11:04 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | PurchaseCommon Stock | 100,000 | $0.44 | $43,700.00 |
DisclosureSEC source: 0001104659-23-000023 · tm2233803d1_4seq1.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 23:16 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 475,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-22-127972 · tm2232925-2_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2029-12-15 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 22:06 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options (right to buy) · Derivative | 650,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001104659-21-153634 · tm2136313-3_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2028-12-23 F1 · shares: These stock options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 36 months. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 16:00 UTC | Elys BMG Group, Inc. ELYS · Entity 91339 | GrantStock Option(right to buy) · Derivative | 13,600 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001017386-21-000394 · ownership.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2031-09-12 F1 · shares: These stock options vest monthly pro rata over 12 months. F1 · derivative.exercise_date: These stock options vest monthly pro rata over 12 months. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:28 UTC | Twin Vee PowerCats, Co. VEEE · Entity 8235 | GrantStock Options · Derivative | 5,500 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001731122-21-001241 · ownership.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2031-06-08 F1 · shares: Consists of options to purchase 5,500 shares of our common stock that vest pro rata on a monthly basis over 12 months. Read SEC document |
| May 10, 2021 Filed May 10, 2021 21:30 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | PurchaseCommon Stock | 50,000 | $0.49 | $24,595.00 |
DisclosureSEC source: 0001104659-21-064047 · tm2115807d1_4.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 10:25 UTC | Elys BMG Group, Inc. NWGI · Entity 91339 | GrantCommon Stock | 5,245 | $5.72 | $30,001.40 |
DisclosureSEC source: 0001017386-21-000023 · ownership.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,245 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive one share of the issuer's common stock, par value $0.0001. The RSUs vest immediately. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:30 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 450,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-20-140996 · tm2039654d3_4seq1.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-12-30 F1 · shares: These stock options will vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These stock options will vest pro rata on a monthly basis over 36 months. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 10:26 UTC | Elys BMG Group, Inc. NWGI · Entity 91339 | GrantStock Option · Derivative | 35,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001017386-20-000403 · ownership.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-09-30 F1 · shares: These options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:54 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 450,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-19-070227 · tm1923941d2_form4.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2026-12-04 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 21:00 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | PurchaseCommon Stock | 50,000 | $0.42 | $20,785.00 |
DisclosureSEC source: 0001144204-19-041677 · tv528238_4.xml · nonDerivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| July 05, 2019 Filed Jul 8, 2019 16:08 UTC Amendment | Elys BMG Group, Inc. NWGI · Entity 91339 | GrantStock Option · Derivative | 82,500 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001017386-19-000189 · ownership.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2029-07-05 F1 · shares: These options vest monthly on a pro rata basis over the next twelve months. Read SEC document |
| July 05, 2019 Filed Jul 8, 2019 12:12 UTC | Elys BMG Group, Inc. NWGI · Entity 91339 | GrantStock Option · Derivative | 2,500 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001017386-19-000186 · ownership.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2029-07-05 F1 · shares: These options vest monthly on a pro rata basis over the next twelve months. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:02 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001144204-18-063628 · tv508646_4.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Director · CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2025-12-06 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:21 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 550,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001144204-17-064830 · tv481807_4.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Interim CEO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2024-12-19 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:02 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 500,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001144204-16-137735 · v454259_4.xml · derivative · entry 1 SHALLCROSS STEVEN A · CIK 0001263501 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2023-11-29 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.